Methotrexate/rituximab

Neutropenia and off-label use: case report

    Reactions Weekly volume 1843, page237(2021)Cite this article

    This is a preview of subscription content, access via your institution.

    Access options

    Buy single article

    Instant access to the full article PDF.

    US$ 49.95

    Tax calculation will be finalised during checkout.

    Reference

    1. Campochiaro C, et al. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology 59: 3731-3736, No. 12, Dec 2020. Available from: URL: http://doi.org/10.1093/rheumatology/keaa136

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Methotrexate/rituximab. Reactions Weekly 1843, 237 (2021). https://doi.org/10.1007/s40278-021-91339-0

    Download citation